We show that MEK inhibition reduces Bregs in vitro and in vivo while preserving anti-tumor humoral immunity in established tumors, and is associated with improved T cell infiltration and response to anti-PD1 immunotherapy. This evidence concerns the gene PDCD1 and neoplasm.